Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleIbrutinib: signifikanter OS-Vorteil gegenüber FCR.PublicationOncology Research & Treatment, 2022, Vol 45, Issue 1/2, p63ISSN2296-5270Publication typeArticleDOI10.1159/000522176